Suppr超能文献

药品报销的当前问题。

Current issues in pharmaceutical reimbursement.

作者信息

Fijalka Steven, Fye David, Johnson Philip E

机构信息

Pharmacy Services, University of Washington Medical Center/Seattle Cancer Care Alliance, Seattle, WA 98195, USA.

出版信息

Am J Health Syst Pharm. 2008 Jan 15;65(2 Suppl 1):S11-26. doi: 10.2146/ajhp070620.

Abstract

PURPOSE

Six issues in pharmaceutical reimbursement arising from recent or proposed changes in Medicare rules or rates or the health care environment are described, along with possible strategies for addressing these issues.

SUMMARY

Recent reductions in Medicare pharmaceutical reimbursement rates, increases in use of specialty pharmacies, proposed changes in rules for erythropoiesis-stimulating agent (ESA) reimbursement, increases in need for patient assistance programs, proposed changes in the clinical trial policy, and possible reductions in reimbursement for cases involving medication errors or other negative events as part of pay-for-performance initiatives are cause for concern. A multidisciplinary team approach to improving reimbursement can reduce institutional financial losses and increase options for Medicare beneficiaries. Health-system pharmacists can address concerns about the use of specialty pharmacies by collaborating with payers and specialty pharmacies on the development of workable models for safely obtaining, handling, and administering medications. Proposed rules for ESA reimbursement contain numerous flaws that could compromise patient outcomes. Pharmacists should provide the Centers for Medicare and Medicaid Services and their fiscal intermediaries with feedback on the potential impact of the proposed rules. The use of patient assistance programs can decrease financial losses associated with providing pharmaceuticals to underinsured or uninsured patients, but these programs can present pharmacists with logistical challenges. The proposed clinical research policy gives priority for research efforts and limited health care dollars to the health issues that are most important to Medicare beneficiaries, but details pertaining to implementation and funding have not yet been worked out. Pharmacists should voice opposition to pay-for-performance models that do not support a nonpunitive culture of openness in reporting quality indicators.

CONCLUSION

An understanding of issues in the current health care environment arising from recent and proposed changes in Medicare rules and rates for pharmaceutical reimbursement can help position pharmacists to manage these issues.

摘要

目的

描述了医疗保险规则或费率近期或拟议的变化或医疗保健环境中出现的六个药品报销问题,以及解决这些问题的可能策略。

总结

医疗保险药品报销费率近期的降低、专科药房使用的增加、促红细胞生成素(ESA)报销规则的拟议变化、患者援助计划需求的增加、临床试验政策的拟议变化,以及作为绩效付费举措一部分,涉及用药错误或其他负面事件的报销可能降低,这些都令人担忧。采用多学科团队方法来改善报销情况,可以减少机构财务损失,并增加医疗保险受益人的选择。卫生系统药剂师可以通过与支付方和专科药房合作,制定安全获取、处理和给药的可行模式,来解决对专科药房使用的担忧。ESA报销的拟议规则存在许多缺陷,可能会损害患者的治疗效果。药剂师应就拟议规则的潜在影响向医疗保险和医疗补助服务中心及其财务中介机构提供反馈。患者援助计划的使用可以减少向未充分投保或未投保患者提供药品所带来的财务损失,但这些计划可能给药剂师带来后勤方面的挑战。拟议的临床研究政策将研究工作和有限的医疗保健资金优先用于对医疗保险受益人最重要的健康问题,但与实施和资金相关的细节尚未确定。药剂师应反对那些不支持报告质量指标时采用非惩罚性公开文化的绩效付费模式。

结论

了解医疗保险药品报销规则和费率近期及拟议变化所引发的当前医疗保健环境中的问题,有助于药剂师应对这些问题。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验